Candidate drugs, perhaps similar to 5-PMFC with combined actions on both HbS stabilization and AQP1 ion channel inhibition, could be valuable starting points for generating affordable clinical options for treating sickle cell disease around the world. This evidence concerns the gene AQP1 and sickle cell disease.